undamentalytics Newsletter
Sign in

Bio-Techne (TECH) stock

Add to watchlist

Add holding +

NASDAQ: TECH Nasdaq Life Sciences Tools & Services Next results ~November 9, 2026

B Fundamentals grade

Bio-Techne is a US-listed company in the life sciences tools & services industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$26

Cash-flow model

Base case. Range ~$19–$34 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 64% below it.

Price used: $72.67, November 2, 2026

Bio-Techne valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Bio-Techne files

10-K/A filed October 28: Bio-Techne

Revenue for the twelve months to June 2026 was $1.22bn, down 0.4% on a year earlier, against growth of 0.2% a quarter earlier. Free-cash-flow margin held at 21.7%. Operating margin widened to 20.7% from 8.4%. Its fundamentals grade moves from C to B. Our model value is little changed at $25.84 a share, against a share price of $72.67. The rating stays Sell. At that price, our model says the market is pricing in about 21.9% a year of cash-flow growth for five years, faster than the 5.5% a year revenue growth it has delivered.

Source: 10-K/A filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Bio-Techne stands after its latest 10-K

Revenue for the twelve months to June 2026 was $1.22bn, down 0.4% on a year earlier, slower than 0.2% a quarter earlier. That puts it 8 of 9 for growth among the life sciences tools & services companies we cover. Free-cash-flow margin held at 21.7%. Operating margin widened to 20.7% from 8.4%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks. Our cash-flow model value is $24.41 a share, against a share price of $72.56. At that price, our model says the market is pricing in about 22.5% a year of cash-flow growth for five years, faster than the 5.5% a year revenue growth it has delivered.

10-K on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Bio-Techne's trailing-twelve-month revenue fell 0.4% year on year, with a free-cash-flow margin of 21.7%. Where it stands out: operating margin of 20.7% ranks 5 of 52 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$26 per share in the base case (~$19–$34 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 2.6% while net income grew 147.7%: a 145pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 12.3 points on a year ago.
  • Strong cash generation. 21.7% of revenue turned into free cash flow, against a median of -1.3% for life sciences tools & services companies we cover.
  • Shrinking share count. Diluted shares fell 1.7% in a year, so each share owns more of the business.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Priced above our value. The share price of $72.67 is 64% above our value per share of $26.
  • Revenue shrinking. Revenue fell 0.4% over the last 12 months.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2026 Q4

Filed August 24, 2026
Earnings per share
$0.52 against an average estimate of $0.52: beat by 0.1%
Revenue
$321m, up 1.3% on a year earlier
Share reaction
0.0% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 9, 2026; average EPS estimate $0.45

Bio-Techne's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.0%
  • 1 week-0.0%
  • 1 month+0.4%
  • This year+24.1%
  • 1 year+16.8%
  • 5 years-41.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2B
Operating margin
20.7%
Net margin
15.0%
EPS (TTM, diluted)
$1.16

Growth

Revenue growth
−0.4%
Change in growth rate
−0.5 pts
Share count change
−1.7%

Cash

Free cash flow (TTM)
$263M
FCF margin
21.7%
Stock pay % of revenue
3.4%

Earnings

Last results
August 12, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Product
  2. Deal
  3. Shareholder vote
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Dividend
  9. Results
  10. Product

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bio-Techne valuation models and calculator

What the price is pricing in

The share price implies about 21.9% a year of cash-flow growth for five years.That is faster than the 5.5% a year revenue growth Bio-Techne has delivered.

  • Priced in21.9%
  • Last 12 months-0.4%
  • 3 years a year2.2%
  • 5 years a year5.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($72.69, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$26
Price used
$72.69close November 3, 2026
Implied change
▼ 64%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Bio-Techne's free cash flow after stock-based pay with after-tax interest added back ($224M, FY2026 Q4 TTM), growing 3.7% and 4.7% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$19–~$34 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Bio-Techne's free cash flow after stock-based pay ( $224M, FY2026 Q4 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Bio-Techne as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$26 ~$19–$34 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$53 ~$42–$69 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$16 ~$11–$22 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$16 ~$14–$19 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$27 ~$16–$53 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bio-Techne with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −25%
  • Revenue growth 5 points higher ▲ +33%
  • Free-cash-flow margin 1 point lower ▼ −4%
  • Last year's free-cash-flow margin change, if it persists ▲ +3%
  • Discount rate 1 point higher ▼ −14%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $21$29$38$51$68$90
8.5% $16$22$29$38$50$66
10% $13$18$23$30$39$51

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026
Share price$26.49$27.94$35.53$50.41$64.23$109.95$84.90$80.28$70.79$51.08$70.57
Market value$4.0bn$4.2bn$5.4bn$7.8bn$10.1bn$17.8bn$13.9bn$13.0bn$11.4bn$8.2bn$11.1bn
+ Net debt (− = net cash)$27m$252m$217m$404m$210m$142m$83m$169m$486m−$162m−$65m
Enterprise value$4.0bn$4.4bn$5.6bn$8.2bn$10.3bn$17.9bn$14.0bn$13.2bn$11.9bn$8.0bn$11.0bn
Multiples
Price / sales 7.9x7.4x8.4x11.0x13.7x19.1x12.6x11.4x9.8x6.7x9.1x
Price / earnings 37.9x55.1x42.9x81.6x44.1x126.8x51.2x45.6x67.7x111.2x60.9x
Price / free cash flow 31.1x32.6x36.2x50.2x66.0x57.8x49.7x60.1x48.2x31.8x42.1x
EV / EBITDA 20.6x24.6x28.0x36.7x43.0x55.2x35.2x32.4x37.3x37.7x31.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

76 /100

Strong moat

How hard Bio-Techne's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 15 / 20

    Cash operating profit has been a median 11.6% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 66.5%, moving by 1.1 percentage points (standard deviation) across 10 years.

  • Durability 12 / 20

    Operating margin has been a median 21.2%; its worst year was 8.4%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 21.8% of revenue.

  • Discipline 14 / 20

    The diluted share count rose 0.9% over five years; stock-based pay has been a median 3.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (81 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, before the open. Analysts expect revenue of $292m and EPS of $0.45 (range $0.41 to $0.49) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.04 +6% $1.3bn +4%
Next $2.31 +14% $1.4bn +10%

Next year's EPS estimate has moved +0.5% in 90 days, across 10 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −0.4% on 90 days ago. In the last 30 days, 2 analysts raised Bio-Techne's forecast and 0 cut it.

Consensus EPS forecast Bio-Techne, last 90 days
$2.00 $2.10 $2.20 $2.30 $2.40 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.05 Current fiscal year, 60 days ago: $2.04 Current fiscal year, 30 days ago: $2.02 Current fiscal year, 7 days ago: $2.04 Current fiscal year, Now: $2.04 $2.04 Next fiscal year, 90 days ago: $2.30 Next fiscal year, 60 days ago: $2.32 Next fiscal year, 30 days ago: $2.31 Next fiscal year, 7 days ago: $2.31 Next fiscal year, Now: $2.31 $2.31

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.05$2.30
60 days ago $2.04$2.32
30 days ago $2.02$2.31
7 days ago $2.04$2.31
Now $2.04$2.31

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.52 $0.52 +0.1%
Mar 2026 $0.53 $0.53 −0.8%
Dec 2025 $0.43 $0.46 +5.8%
Sept 2025 $0.42 $0.42 −0.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 12, 2026

No numeric guidance in Bio-Techne's latest earnings release (filed August 12, 2026). Some companies give their outlook only on the earnings call.

How our valuation uses these forecasts

Our cash-flow model grows Bio-Techne's revenue by +3.7% next year and +4.7% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+4.5%, weight 68%) and the company's own record (+2.0%, weight 32%) . How the weights are set.

Analyst recommendations

13 analysts, Oct 2026
Buy00%
Hold1292%
Sell18%

Monthly trend

  1. Oct 202612113
  2. Sep 202611213
  3. Aug 202611314
  4. Jul 202621214

Counts of recommendations published by analysts covering Bio-Techne, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.8%
of tradable shares
Days to cover
2.42
at average volume
Short interest, 1 month
+14%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.3%
of shares
Employees
3,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +16.8%

$62.22 on October 31, 2025 to $72.67

ThenNowEffect
Revenue (last 12 months) $1.2bn $1.2bn −0.4%
Net margin 6.0% 15.0% +148.7%
P/E multiple 135.4x 62.7x −53.7%
Share count 160m 157m +1.7%

Biggest factor: net margin.

Last 3 years +25.7%

$57.81 on November 3, 2023 to $72.67

ThenNowEffect
Revenue (last 12 months) $1.1bn $1.2bn +6.9%
Net margin 25.1% 15.0% −40.4%
P/E multiple 32.8x 62.7x +91.3%
Share count 162m 157m +3.1%

Biggest factor: p/e multiple.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TECH+63%−36%−7%−6%−18%+24%
Industry peers (median)+4%−53%−3%−15%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TECH75%42%50%42%50%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TECH−16%−45%−41%−21%−41%−39%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 67% from September 24, 2021 to May 15, 2026. Getting back needed a 205% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$43.17 – $72.71
From 52-week high
−0.1%
vs 50-day average
+0.3%
vs 200-day average
+15.2%
Volatility (1 year)
43%
Beta vs S&P 500
0.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±6.3%
After a week
7 up, 5 down
typical move ±6.3%
After a month
7 up, 5 down
typical move ±7.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 0.0% +0.9% +0.5% +0.1%
May 6, 2026 −10.2% +1.1% −20.8% −8.1%
February 4, 2026 +1.9% −1.7% −1.8% −16.5%
November 5, 2025 −4.8% −0.7% +0.5% +1.1%
August 6, 2025 −8.2% +0.7% +0.1% −0.3%
May 7, 2025 +4.3% +1.1% +0.3% +2.2%
February 5, 2025 +3.4% +0.8% −7.0% −11.2%
October 30, 2024 +4.3% −2.3% +7.2% +6.6%
August 7, 2024 −6.4% +1.6% −7.2% −8.7%
May 1, 2024 +19.6% +0.6% +21.9% +22.2%
February 1, 2024 −6.2% +2.4% −3.3% +6.6%
October 31, 2023 −6.7% +1.7% +5.3% +11.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Bio-Techne’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Bio-Techne in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Bio-Techne
$1.1B $1.2B $1.2B $1.2B $1.2B FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue (TTM), FY24 Q1: $1.1B Revenue (TTM), FY24 Q2: $1.1B Revenue (TTM), FY24 Q3: $1.2B Revenue (TTM), FY24 Q4: $1.2B Revenue (TTM), FY25 Q1: $1.2B Revenue (TTM), FY25 Q2: $1.2B Revenue (TTM), FY25 Q3: $1.2B Revenue (TTM), FY25 Q4: $1.2B Revenue (TTM), FY26 Q1: $1.2B Revenue (TTM), FY26 Q2: $1.2B Revenue (TTM), FY26 Q3: $1.2B Revenue (TTM), FY26 Q4: $1.2B $1.2B

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $1.1B
FY24 Q2 $1.1B
FY24 Q3 $1.2B
FY24 Q4 $1.2B
FY25 Q1 $1.2B
FY25 Q2 $1.2B
FY25 Q3 $1.2B
FY25 Q4 $1.2B
FY26 Q1 $1.2B
FY26 Q2 $1.2B
FY26 Q3 $1.2B
FY26 Q4 $1.2B
Revenue growth, TTM YoY Bio-Techne
-2% 0% 2% 4% 6% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Revenue growth, TTM YoY, FY24 Q1: 2.4% Revenue growth, TTM YoY, FY24 Q2: 2.2% Revenue growth, TTM YoY, FY24 Q3: 2.7% Revenue growth, TTM YoY, FY24 Q4: 2.0% Revenue growth, TTM YoY, FY25 Q1: 2.4% Revenue growth, TTM YoY, FY25 Q2: 4.5% Revenue growth, TTM YoY, FY25 Q3: 4.7% Revenue growth, TTM YoY, FY25 Q4: 5.2% Revenue growth, TTM YoY, FY26 Q1: 3.9% Revenue growth, TTM YoY, FY26 Q2: 1.6% Revenue growth, TTM YoY, FY26 Q3: 0.2% Revenue growth, TTM YoY, FY26 Q4: -0.4% -0.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 2.4%
FY24 Q2 2.2%
FY24 Q3 2.7%
FY24 Q4 2.0%
FY25 Q1 2.4%
FY25 Q2 4.5%
FY25 Q3 4.7%
FY25 Q4 5.2%
FY26 Q1 3.9%
FY26 Q2 1.6%
FY26 Q3 0.2%
FY26 Q4 -0.4%
Operating margin (TTM) Bio-Techne
0% 10% 20% 30% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 Operating margin (TTM), FY24 Q1: 26.1% Operating margin (TTM), FY24 Q2: 23.5% Operating margin (TTM), FY24 Q3: 22.1% Operating margin (TTM), FY24 Q4: 17.8% Operating margin (TTM), FY25 Q1: 16.3% Operating margin (TTM), FY25 Q2: 16.7% Operating margin (TTM), FY25 Q3: 14.2% Operating margin (TTM), FY25 Q4: 8.4% Operating margin (TTM), FY26 Q1: 9.0% Operating margin (TTM), FY26 Q2: 9.6% Operating margin (TTM), FY26 Q3: 12.7% Operating margin (TTM), FY26 Q4: 20.7% 20.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 26.1%
FY24 Q2 23.5%
FY24 Q3 22.1%
FY24 Q4 17.8%
FY25 Q1 16.3%
FY25 Q2 16.7%
FY25 Q3 14.2%
FY25 Q4 8.4%
FY26 Q1 9.0%
FY26 Q2 9.6%
FY26 Q3 12.7%
FY26 Q4 20.7%
FCF margin (TTM) Bio-Techne
18% 20% 22% 24% FY24 Q1 FY24 Q4 FY25 Q3 FY26 Q4 FCF margin (TTM), FY24 Q1: 18.8% FCF margin (TTM), FY24 Q2: 19.7% FCF margin (TTM), FY24 Q3: 21.8% FCF margin (TTM), FY24 Q4: 20.4% FCF margin (TTM), FY25 Q1: 20.9% FCF margin (TTM), FY25 Q2: 21.3% FCF margin (TTM), FY25 Q3: 18.3% FCF margin (TTM), FY25 Q4: 21.0% FCF margin (TTM), FY26 Q1: 18.4% FCF margin (TTM), FY26 Q2: 18.3% FCF margin (TTM), FY26 Q3: 22.3% FCF margin (TTM), FY26 Q4: 21.7% 21.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q1 18.8%
FY24 Q2 19.7%
FY24 Q3 21.8%
FY24 Q4 20.4%
FY25 Q1 20.9%
FY25 Q2 21.3%
FY25 Q3 18.3%
FY25 Q4 21.0%
FY26 Q1 18.4%
FY26 Q2 18.3%
FY26 Q3 22.3%
FY26 Q4 21.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2026, from the 10-K

Each dollar Bio-Techne took in during FY2026, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $1.2B
  2. Cost of revenue $416M · 34.2%
  3. Gross profit $799M · 65.8%
  4. Research and development $94.8M · 7.8%
  5. Selling, general and admin $452M · 37.2%
  6. Operating income $252M · 20.7%
  7. Income tax $58.8M · 4.8%
  8. Interest and other $11.2M · 0.9%
  9. Net income $182M · 15.0%

Shares of revenue. Source: Bio-Techne's 10-K for FY2026, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Jun 2010 2011 Jun 2011 2012 Jun 2012 2013 Jun 2013 2014 Jun 2014 2015 Jun 2015 2016 Jun 2016 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 269 290 315 311 358 452 499 563 643 714 739 931 1,106 1,137 1,159 1,220 1,215
Gross profit 214 225 236 231 251 307 337 375 432 473 483 633 756 770 770 790 799
EBITDA 164 172 179 12 179 184 193 181 201 225 240 325 398 406 318 212 349
Operating income 156 163 166 0 160 147 151 121 136 147 157 237 297 299 207 102 252
Net income 110 112 112 113 111 108 104 76 126 96 229 140 272 285 168 73 182
Diluted EPS $0.73 $0.76 $0.76 $0.76 $0.75 $0.72 $0.70 $0.51 $0.83 $0.62 $1.46 $0.87 $1.66 $1.76 $1.05 $0.46 $1.16
Growth (year on year)
Revenue +1.9% +7.8% +8.5% −1.3% +15.2% +26.4% +10.3% +12.8% +14.2% +11.0% +3.5% +26.0% +18.7% +2.8% +2.0% +5.2% −0.4%
EBITDA +3.7% +4.4% +4.0% −93.0% +>999% +3.0% +4.9% −6.6% +11.1% +12.1% +6.8% +35.3% +22.3% +2.1% −21.6% −33.4% +64.6%
Operating income +3.7% +4.3% +1.9% −99.9% — −8.0% +2.4% −19.9% +12.9% +7.7% +7.3% +50.7% +25.0% +0.8% −30.9% −50.5% +146.3%
Net income +4.3% +2.3% +0.0% +0.2% −1.4% −2.9% −3.0% −27.2% +65.8% −23.8% +138.7% −38.8% +93.8% +4.9% −41.1% −56.3% +147.7%
Diluted EPS +5.8% +2.7% +0.7% +0.3% −1.6% −3.7% −3.1% −27.5% +63.1% −25.4% +135.6% −40.2% +90.8% +6.0% −40.3% −56.2% +152.2%
Margins
Gross margin 79.6% 77.6% 75.0% 74.4% 70.3% 67.9% 67.5% 66.5% 67.2% 66.3% 65.4% 68.0% 68.4% 67.7% 66.4% 64.8% 65.8%
EBITDA margin 61.1% 59.2% 56.8% 4.0% 50.0% 40.7% 38.7% 32.1% 31.2% 31.5% 32.5% 34.9% 36.0% 35.7% 27.5% 17.4% 28.7%
Operating margin 58.1% 56.2% 52.8% 0.1% 44.7% 32.5% 30.2% 21.4% 21.2% 20.5% 21.3% 25.5% 26.8% 26.3% 17.8% 8.4% 20.7%
Net margin 40.8% 38.7% 35.7% 36.2% 31.0% 23.8% 20.9% 13.5% 19.6% 13.5% 31.0% 15.1% 24.6% 25.1% 14.5% 6.0% 15.0%
Free-cash-flow margin 39.6% 42.6% 38.4% 32.6% 34.4% 26.4% 25.5% 22.8% 23.2% 21.9% 20.8% 33.1% 25.4% 19.0% 20.4% 21.0% 21.7%
Cash flow
Cash from operations 111 127 127 124 137 139 144 144 170 182 205 352 325 254 299 288 292
Capital spending 5 4 6 22 14 20 17 15 21 25 52 44 45 38 63 31 29
Free cash flow 107 124 121 101 123 119 127 129 149 156 153 308 280 216 236 257 263
Stock-based pay 1 1 2 2 4 6 9 15 28 32 32 49 42 39 38 41 41
Free cash flow after stock pay 106 122 119 99 119 113 118 114 121 124 121 259 238 177 198 216 222
Balance sheet
Cash 94 78 117 164 319 55 64 92 122 101 147 199 173 181 152 162 265
Total debt 0 0 0 0 0 73 92 344 339 505 357 341 256 350 638 — 200
Net debt (negative = net cash) −94 −78 −117 −164 −319 18 27 252 217 404 210 142 83 169 486 −162 −65
Diluted shares 149m 149m 148m 148m 148m 149m 149m 150m 152m 156m 158m 162m 164m 162m 161m 160m 157m
Returned to shareholders
Dividends 38 40 41 43 45 47 48 47 48 48 49 50 50 50 50 50 50
Buybacks 15 2 24 2 0 0 — — 0 15 50 43 161 20 80 276 42
Total returned 53 42 65 45 45 47 48 47 48 64 99 93 211 70 130 326 92

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 6 checks passed · June 30, 2026
What it owns · $2.6bn
Short-term assets $744mLonger-term assets $1.8bn
What it owes, and who funded it · $2.3bn
Short-term liabilities $164mShareholders' equity $2.1bn
  • Short-term assets cover short-term liabilities $744m of assets due within a year against $164m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $265m of cash against $200m of debt.
  • Debt below 40% of shareholders' equity Debt is 9% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 16% to 9% over five years.
  • A year's operating cash flow covers at least 20% of debt $292m of operating cash flow against $200m of debt.
  • Operating profit covers interest at least five times over Operating income of $252m against $10m of interest.

From Bio-Techne's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q4 TTM
Buybacks (TTM)
$41.7M
Dividends (TTM)
$49.9M
Returned to shareholders
35%
of free cash flow
Buybacks, last 3 fiscal years
$397M
Diluted share count
−1.7%
year over year
Total shareholder yield
0.8%
dividends 0.4% + buybacks 0.4% of market value
Dividend payout ratio
28%
of net income paid out
R&D spending
7.8%
of revenue
Sales & admin spending
37.2%
of revenue
Days sales outstanding
65 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated TECH SHC RGEN NEO QGEN TXG Median
Revenue, last 12 months $1.2bn $1.2bn $806m $788m $2.1bn $617m $229m
Revenue growth, last 12 months −0.4% 8.1% 13.8% 11.1% 5.7% −4.3% 6.9%
Revenue growth, 3-year average 2.2% 7.6% 7.3% 11.1% 17.1% 2.8% 2.9%
Revenue growth, latest quarter 1.3% 9.2% 10.9% 11.4% — −12.6% 8.5%
Gross margin 65.8% 55.0% 53.5% 44.8% 62.2% 70.0% 51.9%
Operating margin 20.7% 27.0% 2.3% −6.3% 22.3% −14.3% −14.3%
Operating margin, 3-year average 15.6% 26.1% 1.4% −12.5% 20.4% −23.3% −22.4%
Net margin 15.0% 13.4% −1.5% −4.1% 20.3% −12.2% −16.1%
Cash from operations / revenue 24.0% 24.0% 16.1% 0.5% 31.3% 20.6% 1.3%
Free-cash-flow margin 21.7% 9.3% 13.2% −3.6% 21.7% 19.7% −2.2%
Free-cash-flow margin, 3-year average 21.0% 7.4% 16.6% −3.1% 18.5% 7.8% 0.6%
Stock pay / revenue 3.4% 3.1% 4.2% 4.4% 2.4% 16.0% 4.4%
Change in share count −1.7% 1.0% 0.3% 1.2% −2.6% 4.2% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -0.4% 6.9% 43 of 54
Change in growth rate Growth -0.5pp +0.4pp 35 of 54
Gross margin Profitability 65.8% 52.0% 8 of 45
Operating margin Profitability 20.7% -14.3% 5 of 52
Net margin Profitability 15.0% -12.2% 8 of 54
Free-cash-flow margin Cash generation 21.7% -1.3% 6 of 54
Stock pay as % of revenue Cash generation 3.4% 4.4% 22 of 53
Long-term debt as % of assets Balance sheet 7.7% 26.3% 8 of 35
Change in share count Balance sheet -1.7% 1.0% 10 of 46
Days sales outstanding Balance sheet 65 days 62 days 30 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to June 30, 2026
Products and services
Line of business Revenue Share YoY
Product and Services $1.2B 97.9% ▼ 0.5%
Consumables $985M 82.8% ▲ 1.3%
Instruments $111M 9.3% ▼ 1.3%
Services $94.3M 7.9% ▼ 15.5%
Royalty $25M 2.1% ▲ 5.5%
Geography
Region Revenue Share YoY
United States $635M 52.3% ▼ 7.0%
EMEA Excluding UK $294M 24.2% ▲ 10.5%
China $104M 8.6% ▲ 3.6%
APAC Excluding Greater China $85.8M 7.1% ▲ 11.1%
United Kingdom $56.3M 4.6% ▲ 2.7%
Rest of World $39.3M 3.2% ▲ 4.6%

From Bio-Techne's 10-K filed August 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$12.3B
Institutions reporting
590
Shares held vs prior quarter
▼ 0.5%
Positions opened / closed
120 / 110

Top buyers and sellers, Q2 2026: 281 institutions bought and 349 sold ; the biggest buyer was HBK Investments L P (+6.8M shares) and the biggest seller Wellington Management Group LLP (−5.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $991M 14.0M 8.1% ▲ 14.4%
FMR LLC $904M 12.8M 7.4% ▲ 62.0%
Vanguard Capital Management LLC $722M 10.2M 5.9% ▲ 0.4%
Goldman Sachs Group Inc $519M 7.3M 4.2% ▲ 277.8%
HBK Investments L P $482M 6.8M 3.9% New
Vanguard Portfolio Management LLC $460M 6.5M 3.7% ▲ 0.4%
Morgan Stanley $450M 6.4M 3.7% ▼ 25.3%
State Street Corp $423M 6.0M 3.4% ▲ 1.9%
Geode Capital Management, LLC $378M 5.4M 3.1% ▲ 4.7%
Invesco Ltd. $352M 5.0M 2.9% ▲ 8.7%
Ruane, Cunniff & Goldfarb L.P. $237M 3.3M 1.9% ▼ 1.3%
Snyder Capital Management L P $224M 3.2M 1.8% ▲ 68.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bio-Techne's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $437,178 2 trades by 1 insider · 0% under pre-set plans
Net ▼ $437,178 net selling
Insider Date Trade Shares Price Value
Herr Amy E. Director May 8, 2026 Sell 6,636 $48.28 $320,386
Herr Amy E. Director February 17, 2026 Sell 1,976 $59.10 $116,791

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 16 trades and filings

In the last 12 months, 1 member of Congress disclosed 2 purchases and 4 sales of Bio-Techne shares.

  • April McClain Delaney(D-MD 6):Sale (full), $1,001 - $15,000, traded April 8, 2026, filed May 6, 2026
  • April McClain Delaney(D-MD 6):Sale (partial), $1,001 - $15,000, traded March 26, 2026, filed April 6, 2026
  • April McClain Delaney(D-MD 6):Sale (partial), $1,001 - $15,000, traded February 24, 2026, filed March 10, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 6, 2026
  • February 4, 2026
  • November 5, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Bio-Techne was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bio-Techne in brief

What does Bio-Techne do?
Bio-Techne is a US-listed company in the life sciences tools & services industry. Its financial year ends in June.
What is Bio-Techne's stock ticker?
Bio-Techne trades under the ticker TECH on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Bio-Techne's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Bio-Techne reported revenue of $1.2B, 0.4% lower than a year earlier, according to its SEC filings.
What is Bio-Techne's free cash flow?
Bio-Techne's free-cash-flow margin is 21.7% of revenue over the trailing twelve months, ranking 6 of the 54 life sciences tools & services companies we cover.
What is Bio-Techne's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Bio-Techne's free cash flow after stock-based pay gives ~$26 per share in the base case, and ~$19–$34 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Bio-Techne's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., FMR LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Bio-Techne buying back stock, and does it pay a dividend?
Bio-Techne spent $41.7M on share repurchases over the trailing twelve months, and its diluted share count fell 1.7% over the year.
What is Bio-Techne's market cap?
On June 30, 2026, Bio-Techne's market capitalisation was about $11.1B, with a price-to-earnings ratio of 60.9 and net debt of -$64.7M. Market figures come from third-party market data and may be delayed.
Does Bio-Techne pay a dividend?
Yes: Bio-Techne paid $49.9M in dividends over the trailing twelve months, a dividend yield of 0.44% and a payout ratio of 27.5%.
How much debt does Bio-Techne have?
Bio-Techne's debt-to-equity ratio is 9.5%, from its latest balance sheet (15.8% five years earlier). The financial health section below sets out its other solvency checks.
Who are Bio-Techne's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Bio-Techne are Sotera Health Co, Repligen Corp, Neogenomics Inc, Qiagen N.V. and 10x Genomics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Bio-Techne's.
Are insiders buying or selling Bio-Techne stock?
Over the last 12 months, Bio-Techne's directors and officers reported 0 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Bio-Techne's next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bio-Techne announces its own schedule.